 |
Prospector
Profile
08.0016
|
| |
| PhytoMedical Technologies, Inc. |
NAICS |
541710 |
| 100 Overlook Drive, 2nd Floor
Princeton, NJ 08540 |
Description |
Biotechnology |
| (604) 659-5004 |
Employees |
5 |
| http://www.phytomedical.com/ |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-3.8520 |
| |
Assets |
(mil) |
0.4200 |
| |
Liability |
(mil) |
1.6010 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Phytomedical Technologies, Inc. reported a net loss of $353,094 for the third quarter ended Sept. 30, 2007, compared with a net loss of $993,923 in the same period last year. The company has yet to establish any history of profitable operations. The company had no revenues during the last three fiscal years and it does do not expect to generate revenues from
operations for the foreseeable future. At Sept. 30, 2007, the company's consolidated balance sheet showed $3.14 million in total assets, $1.66 million in total liabilities, and $1.48 million in total stockholders' equity.
|
| |
|
Intellectual Property:
On May 25, 2007, the Company entered into a research agreement with Dartmouth College, in the area of cancer research, specifically furthering research and development of anti-cancer agents which have a ‘cytotoxic’ or poisonous affinity for cancer cells, using bis-acridines, a set of compounds known to bind to cancer DNA. Dartmouth granted the Company the option of a world-wide, royalty-bearing exclusive license to make, have made, use and sell in the field of oncology, the products embodying or produced through Dartmouth’s previous and future patents and through any joint-inventions related to the research agreement. [SEC Filing SB-2 11-09-07]
|
| |
|
Description:
PhytoMedical Technologies operates as an early stage research-based biopharmaceutical company.
|
| |
|
Officers:
Greg Wujek (Pres., CEO & Dir.); Harmel S. Rayat (Sec., Treas. & Dir.); Gary Branning (Dir.); Raymond Krauss (Dir.)
|
| |
|
Auditor:
Peterson Sullivan PLLC
|
| |
|
Securities:
Common Stock-Symbol PYTO.OB; OTC BB;
200,398,288 common shares outstanding as of November 7, 2007.
|
| |
| |
| |
| return to main page |
|
|
